Brain+

0,021

DKK

+5,05 %

Mindre end 1K følgere

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+5,05%

-41,24%

-50,79%

-55,41%

-57,32%

-65,6%

-97,58%

-

-98,48%

Brain + er aktiv i medicinalindustrien. Virksomheden har specialiseret sig i forskning og udvikling til behandling af demens og Alzheimers. Produktporteføljen omfatter f.eks. Kognitiv stimuleringsterapi. Forretningen drives med den største tilstedeværelse i Europa.

Markedsværdi

13,58 mio. DKK

Aktieomsætning

34,64 t DKK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

29.4

2025

Årsrapport '24

29.5

2025

Generalforsamling '25

28.8

2025

Delårsrapport Q2'25

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse16.4.2025, 09.15

Brain+ A/S: Brain+ appoints CCO Devika Wood as new CEO

Selskabsmeddelelse9.4.2025, 06.50

Brain+ A/S: Brain+ announces directed issue of units to convertible loan providers and guarantors

Pressemeddelelse3.4.2025, 06.41

Brain+ A/S: Contract signed with Copenhagen Municipality on extended and expanded access to Ayla

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse2.4.2025, 06.47

Brain+ A/S: Brain+ announces outcome of unit rights issue

Pressemeddelelse26.3.2025, 07.35

Brain+ A/S informs of last day to subscribe in its ongoing rights issue of units

Pressemeddelelse25.3.2025, 11.56

Brain+ A/S: Brain+ to close first UK Care Home partnership contract with Southcare Homes Group

Pressemeddelelse19.3.2025, 13.44

Brain+ A/S: Invitation to investor webinar to present new Board Observer, sales pipeline progress and ongoing Unit Rights Issue

Pressemeddelelse19.3.2025, 07.42

Brain+ A/S: Brain+ expands its UK sales pipeline to €+500,000 in revenue and reveals Key Performance Indicators

Selskabsmeddelelse17.3.2025, 07.59

Brain+ A/S: The subscription period in Brain+' rights issue of units begins today

Pressemeddelelse11.3.2025, 09.54

Brain+ A/S: UK care sector expert, Vishal Shah joins Brain+ as Advisor and Board Observer

Pressemeddelelse10.3.2025, 07.31

Brain+ A/S: The benefits of Ayla - your CST Assistant featured in CareTech, the healthtech media for Danish healthcare professionals

Selskabsmeddelelse6.3.2025, 07.50

Brain+ A/S: Brain+ resolves to carry out its earlier announced unit rights issue of up to approximately DKK 16 million

Selskabsmeddelelse12.2.2025, 11.02

Brain+ A/S - Minutes of Extraordinary General Meeting

Pressemeddelelse30.1.2025, 12.47

Brain+ A/S: Invitation to Investor Webinar to update on sales outlook, restructuring and secured funding

Selskabsmeddelelse28.1.2025, 17.33

Brain+ A/S - Notice of Extraordinary General Meeting

Selskabsmeddelelse22.1.2025, 18.30

Brain+ A/S: Brain+ restructures to reduce OPEX by 35%, maintaining €1M ARR target for end 2025 and now expecting break-even by mid-2026, and announces 50% secured intended Rights Issue

Selskabsmeddelelse31.12.2024, 13.30

Brain+ A/S: Brain+ announces change of Certified Advisor

Pressemeddelelse10.12.2024, 07.45

Brain+ A/S: Brain+ invites to investor webinar to update on UK commercial pipeline and status

Pressemeddelelse5.12.2024, 07.51

Brain+ A/S: Brain+ secures its first multi-year sales contract for Ayla - your CST Assistant with Syddjurs municipality

Pressemeddelelse21.11.2024, 14.30

Brain+ A/S: Invitation to Investor Webinar on Monday 25th of November at 15:30: Update on commercial status and new opportunities

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.